Your session is about to expire
← Back to Search
Iron Supplement
Ferumoxytol injection for Anemia (AMAGFeraheme Trial)
Phase 4
Waitlist Available
Led By Stuart Katz, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved
Pivotal Trial
Approved for 5 Other Conditions
Drug Has Already Been Approved
Summary
This trial is testing a new way to give iron supplements to people who have had a heart device put in, to see if it's better than the old way.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Ferumoxytol injection treatmentExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,410 Previous Clinical Trials
855,605 Total Patients Enrolled
Stuart Katz, MDPrincipal InvestigatorNew York Langone Medical Center
9 Previous Clinical Trials
607 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger